BRPI0820343A2 - Anticorpos de antifator b e seus usos - Google Patents

Anticorpos de antifator b e seus usos

Info

Publication number
BRPI0820343A2
BRPI0820343A2 BRPI0820343A BRPI0820343A BRPI0820343A2 BR PI0820343 A2 BRPI0820343 A2 BR PI0820343A2 BR PI0820343 A BRPI0820343 A BR PI0820343A BR PI0820343 A BRPI0820343 A BR PI0820343A BR PI0820343 A2 BRPI0820343 A2 BR PI0820343A2
Authority
BR
Brazil
Prior art keywords
antibodies
factor
antifactor
cnv
amd
Prior art date
Application number
BRPI0820343A
Other languages
English (en)
Inventor
Deforge Laura
Van Lookeren Campagne Menno
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820343(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0820343A2 publication Critical patent/BRPI0820343A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS DE ANTIFATOR B E SEUS USOS. A invenção refere-se à prevenção e tratamento de condição de olho associada a complementos, tais como neovascularização da coroide (CNV) e degeneração macular relacionada à idade (AMD), por administração de antagonistas de fator B.
BRPI0820343A 2007-11-08 2008-11-06 Anticorpos de antifator b e seus usos BRPI0820343A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (1)

Publication Number Publication Date
BRPI0820343A2 true BRPI0820343A2 (pt) 2017-08-22

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820343A BRPI0820343A2 (pt) 2007-11-08 2008-11-06 Anticorpos de antifator b e seus usos

Country Status (15)

Country Link
US (4) US8158762B2 (pt)
EP (1) EP2209807A1 (pt)
JP (1) JP2011503094A (pt)
KR (1) KR20100105587A (pt)
CN (1) CN101918444A (pt)
AR (1) AR069233A1 (pt)
AU (1) AU2008323939A1 (pt)
BR (1) BRPI0820343A2 (pt)
CA (1) CA2704973A1 (pt)
CL (1) CL2008003313A1 (pt)
IL (1) IL205577A0 (pt)
MX (1) MX2010005115A (pt)
PE (1) PE20091022A1 (pt)
TW (1) TW200927170A (pt)
WO (1) WO2009061910A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
WO2013177035A2 (en) * 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
US10934347B2 (en) * 2016-04-04 2021-03-02 Genzyme Corporation Anti-complement factor BB antibodies and uses thereof
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021216458A1 (en) 2020-04-20 2021-10-28 Genzyme Corporation Humanized anti-complement factor bb antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
CA3009846C (en) * 2006-03-08 2021-08-31 David Epstein Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US20100120665A1 (en) * 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation

Also Published As

Publication number Publication date
EP2209807A1 (en) 2010-07-28
US20180037667A1 (en) 2018-02-08
CN101918444A (zh) 2010-12-15
MX2010005115A (es) 2010-05-27
WO2009061910A1 (en) 2009-05-14
AR069233A1 (es) 2010-01-06
US20160024224A1 (en) 2016-01-28
TW200927170A (en) 2009-07-01
CL2008003313A1 (es) 2010-02-05
AU2008323939A1 (en) 2009-05-14
IL205577A0 (en) 2010-11-30
US20090123469A1 (en) 2009-05-14
US20120230997A1 (en) 2012-09-13
KR20100105587A (ko) 2010-09-29
US8158762B2 (en) 2012-04-17
PE20091022A1 (es) 2009-07-16
JP2011503094A (ja) 2011-01-27
CA2704973A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
CY1116062T1 (el) Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα
BRPI0820343A2 (pt) Anticorpos de antifator b e seus usos
MX2021011394A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
WO2012100142A3 (en) Treatments for retinal disorders
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
PH12013501436A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
MY171920A (en) Prevention and treatment of ocular conditions
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
WO2009097468A3 (en) Drug delivery devices, kits and methods therefor
BR112014008759A2 (pt) tratamento de doença ocular
WO2007133800A3 (en) Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
CR20110294A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda
MY184647A (en) Arylated camphenes, processes for their preparation and uses thereof
CR20110289A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.